Repros Therapeutics, Inc. (RPRX)

[iwfal]

From their PR today:

Additional secondary findings within the “benign” category were noted, the most prominent being the presence of cystic dilatation of glands similar to the histological pattern recently described for women treated with other Progesterone Receptor Modulators (PRMs) such as asoprisnil, mifepristone and CBD 2914 (VA2914).2,3,4

This brings up an area of research I still need to understand - the competition. I already knew RU-486 (mif) had a trial for UF. Don't know about the others, but it would be good to understand any trials they are in ... .

Proellex® did not induce, however, the blood vessel wall thickening and latticed capillary patterns seen with some other progesterone receptor modulators.

? Anyone have an explanation for that? Why one would be better than another? Unlike, say, statins which seem to operate through several mechanisms, Progesterone modulation would seem to be something that should be pretty straight forward. (I say that knowing that mif also affects the HPA axis - but that seems far distant from the endometrium.). Probably a question for which it is unreasonable to expect a complete answer - but in the current FDA environment it may be useful to have some possible explanations.

PS To JP if he is reading this - ignore DM's tweaking about the PR being hard to read -g-. I, for one, appreciate duplicate data presented from a new angle as long as it isn't passed off as entirely new.

PPS Corp - Don't worry, my vetting process only lasts a month or two. Then I'll dramatically slow my rate of questioning posts - but I hope you don't mind if I never switch to Rah, rah, rah! -g-